Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.

Condition:   Triple Negative Breast Cancer Interventions:   Biological: adagloxad simolenin combined with OBI-821;   Biological: Phosphate-buffered saline (PBS) Sponsor:   OBI Pharma, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials